ANT-005 TKA (mid-dose)
Trial question
Is abelacimab superior to enoxaparin in the prevention of VTE in patients undergoing total knee arthroplasty?
Study design
Multi-center
Open label
RCT
Population
Characteristics of study participants
80.2% female
19.8% male
N = 200
200 patients (161 female, 39 male)
Inclusion criteria: patients aged 18-80 years who were undergoing elective primary unilateral total knee arthroplasty
Key exclusion criteria: active bleeding or high risk of bleeding; history of VTE; an eGFR < 60 mL/min/1.73 m²; clinically significant liver disease
Interventions
N=99 abelacimab (a single intravenous dose of 75 mg once daily)
N=101 enoxaparin (a subcutaneous dose of 40 mg once daily)
Primary outcome
Venous thromboembolism
5
22
22.0 %
16.5 %
11.0 %
5.5 %
0.0 %
Abelacimab
Enoxaparin
Significant decrease ▼
NNT = 5
Significant decrease in VTE (5% vs. 22%; ARD -16.8, 95% CI -26 to -7.6)
Safety outcomes
No significant differences in ≥ 1 adverse event, major or clinically relevant nonmajor bleeding, frequency of blood transfusions.
Conclusion
In patients aged 18-80 years who were undergoing elective primary unilateral total knee arthroplasty, abelacimab was superior to enoxaparin with respect to VTE.
Reference
Peter Verhamme, B Alexander Yi, Annelise Segers et al. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 Aug 12;385(7):609-617.
Open reference URL